213Bi-DOTA-物质P靶向α治疗复发胶质母细胞瘤的安全性与疗效
治疗耐受良好,仅见轻微短暂不良反应;复发后中位生存10.9个月,自开始治疗起中位生存7.5个月。
要点
- 213Bi-DOTA-物质P治疗复发GBM耐受良好,仅见轻微短暂不良反应。
- 复发后中位总生存10.9个月,自治疗开始中位生存7.5个月。
- 中位无进展生存2.7个月,自首次诊断中位总生存23.6个月。
核心结论
- 213Bi-DOTA-物质P治疗复发胶质母细胞瘤安全且耐受良好。
- 复发后中位总生存10.9个月,与现有替代治疗方案相比具有优势。
- 在确保高活度225Ac/213Bi放射性核素发生器供应后,该靶向α治疗可能成为复发GBM有前景的新选择。
研究设计与样本
- 经立体定向置入1-2个腔内或瘤内port-a-cath系统。
- 患者接受1-7剂213Bi-DOTA-物质P治疗,间隔2个月。
- 联合注射68Ga-DOTA-物质P,用PET/CT评估生物分布。
- 通过体能状态和MRI监测治疗反应。
主要发现
- 治疗活度最高达11.2 GBq的213Bi-DOTA-物质P耐受良好,仅见轻微短暂不良反应。
- 中位无进展生存期为2.7个月。
- 自首次诊断起中位总生存为23.6个月。
- 复发后中位生存为10.9个月。
- 自开始213Bi-DOTA-物质P治疗起中位生存时间为7.5个月。
关键数值与推荐
- 治疗活度最高达11.2 GBq。
- 中位无进展生存2.7个月,复发后中位生存10.9个月。
- 自首次诊断中位总生存23.6个月,自治疗开始中位生存7.5个月。
临床怎么用
- 对标准治疗后复发GBM患者,可考虑213Bi-DOTA-物质P靶向α治疗作为安全可选方案。
- 治疗前经立体定向置入腔内或瘤内导管,联合68Ga-DOTA-物质P PET/CT评估生物分布。
- 治疗期间通过体能状态和MRI监测反应,注意活度最高达11.2 GBq时仅见轻微短暂不良反应。
局限性
- 高活度225Ac/213Bi放射性核素发生器的供应尚未确保。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Treatment options for recurrent glioblastoma multiforme (GBM) are very limited. GBM cells express high levels of the GPCR neurokinin type 1 receptor (NK-1R), and a modified substance P can be used as its ligand for the tumor cell targeting. Targeted alpha therapy with DOTA-Substance P labeled with the short range alpha emitter 213Bi allows for selective irradiation and killing of tumor cells. MATERIAL AND METHODS: Twenty patients with recurrent GBM were included into the study following a standard therapy. 1-2 intracavitary or intratumoral port-a-cath systems were stereotactically inserted. Patients were treated with 1-7 doses of 213Bi-DOTA-Substance P (213Bi-DOTA-SP) in 2-month intervals. 68Ga-DOTA-Substance P (68Ga-DOTA-SP) was co-injected with 213Bi-DOTA-SP to assess the biodistribution using PET/CT. Therapeutic response was monitored with performance status and MRI imaging. RESULTS: Treatment with activity up to 11.2 GBq 213Bi-DOTA-SP was well tolerated with only mild and transient adverse reactions. The median progression free survival was 2.7 months. The median overall survival from the first diagnosis was 23.6 months and median survival after recurrence was 10.9 months. The median survival time from the start of 213Bi-DOTA-SP was 7.5 months. CONCLUSIONS: Treatment of recurrent GBM with 213Bi-DOTA-SP is safe and well tolerated. The median overall survival after recurrence of 10.9 months compares favorably to the available alternative treatment options. Once the supply of high activity 225Ac/213Bi radionuclide generators is secured, targeted alpha therapy with 213Bi-DOTA-SP may evolve as a promising novel option to treat recurrent GBM.
引用
- Królicki L, Bruchertseifer F, Kunikowska J, et al. Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma. Eur J Nucl Med Mol Imaging. 2018. PMID: 30498897. doi:10.1007/s00259-018-4225-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。